Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

Antiresorptive medication in oncology: the clinical and dental profile of patients in a reference center

  • Received : 2020.07.13
  • Accepted : 2020.08.29
  • Published : 2021.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: The aim of this study was to evaluate the profile of patients on antiresorptive therapies for cancer treatment and assess presence of oral lesions, oral hygiene status, and knowledge regarding medication-related osteonecrosis of the jaw (MRONJ). Materials and Methods: This was an observational cross-sectional study that evaluated patients treated with antiresorptive medication at a single cancer hospital. Clinical data were collected and oral examination was performed to assess patient oral health. Results: From July 2017 to December 2018, 90 patients were assessed; 64 were female and 26 were male, and the mean age was 61 years. The most common drug was an intravenous bisphosphonate, zoledronic acid. Among the 90 patients, 47 presented with some type of oral disease, isolated or associated. Among these 47 patients, 9 patients (10%) developed osteonecrosis. Oral hygiene was evaluated, and most patients, with or without MRONJ, presented with regular to poor condition. Regarding patient knowledge of the risks of MRONJ and the risks associated with dental surgery, 60% stated that they were not aware of the risks. Conclusion: Identifying the profile of patients and their needs facilitates not only the preventive process, but also the emergence of new therapeutic options. Our study shows that most patients are weakened both by metastatic disease and antineoplastic treatment as well as by issues associated with aging because most were over 60 years of age. Collectively, this information should be considered for management of preventive and therapeutic measures.

Keywords

References

  1. Nicolatou-Galitis O, Schiodt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol 2019;127:117-35. https://doi.org/10.1016/j.oooo.2018.09.008
  2. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80(8 Suppl):1588-94. https://doi.org/10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.3.co;2-z
  3. Sahin O, Odabasi O, Aliyev T, Tatar B. Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation. J Korean Assoc Oral Maxillofac Surg 2019;45:108-15. https://doi.org/10.5125/jkaoms.2019.45.2.108
  4. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-56. https://doi.org/10.1016/j.joms.2014.04.031
  5. Nifosi AF, Zuccarello M, Nifosi L, Hervas Saus V, Nifosi G. Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology. J Korean Assoc Oral Maxillofac Surg 2019;45:3-8. https://doi.org/10.5125/jkaoms.2019.45.1.3
  6. Al Abdullateef A, Alhareky MS. Awareness among patient at risk of developing Medication Related Osteonecrosis of the Jaw (MRONJ) - a primary prevention strategy. Saudi Pharm J 2020;28:771-8. https://doi.org/10.1016/j.jsps.2020.05.004
  7. Sturrock A, Preshaw PM, Hayes C, Wilkes S. Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England. BMJ Open 2019;9:e024376. https://doi.org/10.1136/bmjopen-2018-024376
  8. Greene JC, Vermillion JR. The simplified oral hygiene index. J Am Dent Assoc 1964;68:7-13. https://doi.org/10.14219/jada.archive.1964.0034
  9. Patel V, Kelleher M, Sproat C, Kwok J, McGurk M. New cancer therapies and jaw necrosis. Br Dent J 2015;219:203-7. https://doi.org/10.1038/sj.bdj.2015.680
  10. Heufelder MJ, Hendricks J, Remmerbach T, Frerich B, Hemprich A, Wilde F. Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 2014;117:e429-35. https://doi.org/10.1016/j.oooo.2012.08.442
  11. Tsao C, Darby I, Ebeling PR, Walsh K, O'Brien-Simpson N, Reynolds E, et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg 2013;71:1360-6. https://doi.org/10.1016/j.joms.2013.02.016
  12. Sandhu S, Salous MH, Sankar V, Margalit DN, Villa A. Osteonecrosis of the jaw and dental extractions: a single-center experience. Oral Surg Oral Med Oral Pathol Oral Radiol 2020;130:515-21. https://doi.org/10.1016/j.oooo.2020.07.001
  13. Poubel VLDN, Silva CAB, Mezzomo LAM, De Luca Canto G, Rivero ERC. The risk of osteonecrosis on alveolar healing after tooth extraction and systemic administration of antiresorptive drugs in rodents: a systematic review. J Craniomaxillofac Surg 2018;46:245-56. https://doi.org/10.1016/j.jcms.2017.11.008
  14. Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G, et al. Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci 2011;1218:62-79. https://doi.org/10.1111/j.1749-6632.2010.05835.x
  15. Gaudin E, Seidel L, Bacevic M, Rompen E, Lambert F. Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis. J Clin Periodontol 2015;42:922-32. https://doi.org/10.1111/jcpe.12455
  16. Tsurushima H, Kokuryo S, Sakaguchi O, Tanaka J, Tominaga K. Bacterial promotion of bisphosphonate-induced osteonecrosis in Wistar rats. Int J Oral Maxillofac Surg 2013;42:1481-7. https://doi.org/10.1016/j.ijom.2013.06.011
  17. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009;20:117-20. https://doi.org/10.1093/annonc/mdn554
  18. Bramati A, Girelli S, Farina G, Dazzani MC, Torri V, Moretti A, et al. Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. J Bone Miner Metab 2015;33:119-24. https://doi.org/10.1007/s00774-014-0566-x